Havn Life (CSE: HAVN): The Future of Psychedelic Medicine HAVN Life is part of a global community taking an active role in formulations and research for microdosing therapies which have shown effectiveness in addressing mental health and performance
HAVN Life Enters into Definitive Agreement to Acquire Spore Life . . . Vancouver, BC – Havn Life Sciences Inc (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “Havn Life”), a biotechnology company developing natural health products and innovative therapies to support central nervous system health and enhance the capabilities of the mind, is pleased to announce it has entered into a definitive
HAVN Life Announces Retail Partnership with Alberta Grocer, Calgary Co . . . The Company’s full line of natural health formulations will be available at select locations starting in May Vancouver, BC – Havn Life Sciences Inc (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “HAVN Life”) a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural health products, is pleased to announce […]
HAVN Life Announces Gary Leong’s Appointment to Board of Directors Mr Leong has been instrumental in the regulatory development and launch of HAVN Life’s Retail Division, formulating its portfolio of natural health products, launched in June of 2021 Gary Leong has more than thirty years of experience in the pharmaceutical and natural health product industries
Havn Life Announces Strategic Clinical Trial Partnership with . . . Havn Life will assist HealthTech Connex in expanding the use of NeuroCatch technology to psilocybin clinical trials “We’re thrilled to enter into this strategic partnership,” noted Tim Moore, CEO of Havn Life
Havn Life Sciences undertakes one of the first preclinical studies on . . . The Company’s science division, Havn Research, is undertaking a study to determine if a single dose of psilocybin extract can impact the body’s inflammatory response and regulate the human immune system The Havn Life team will begin this preclinical study in Q1 2021
Press Releases Archives - Havn Life Vancouver, BC – July 24, 2023 – Havn Life Sciences Inc (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “HAVN Life”), a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural health products, is pleased to announce that, effective as of July 4, 2023 (the “Effective
Havn Life Sciences granted Section 56 exemption to begin scientific . . . Havn Life intends to immediately begin work on experiments with the objective of developing a set of methods for the safe, standardized, quality-controlled production of medical compounds extracted from the Psilocybe spp mushroom
HAVN ANNOUNCES ANTICIPATED LATE FILING OF FINANCIAL STATEMENTS AND . . . Vancouver, BC – HAVN Life Sciences Inc (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the “Company” or “HAVN Life”), a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural health products, announces it anticipates that it will miss the deadline (the “Filing Deadline”) of August 28, 2023, to file the following (collectively, […]